title: Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more?
abstract: BACKGROUND
  An increasing incidence and controversial interpretations about the valuation of improved survival rates are the main subjects of the discussion dealing with the epidemiology of the prostate carcinoma. In this study the most recent data of the Cancer Registry Schleswig-Holstein (the northernmost state of Germany) are introduced.
  
  
  METHODS
  Data from the population-based cancer registry covering a population of 2.8 million inhabitants were evaluated descriptively for the years 1999-2005.
  
  
  RESULTS
  The frequency of more prognostic favourable diagnosis rose in the analyzed period. In 2000-2001, 62.9% of the patients were diagnosed with stage I/II and in 2004-2005 the percentage rose to 67.9%. From 1999 to 2003 the age-adjusted incidence increased by 30% and declined to the level of 1999 within 2 years. Mortality decreased continuously and from 1999 to 2005 it dropped by 20%.
  
  
  CONCLUSIONS
  We assume that a selected group of men in Schleswig-Holstein has been screened regularly by PSA testing. The rise of incidence could be interpreted as a typical effect of a screening prevalence round. Thereafter the incidence declined because of the initial screening effect. However, it is not yet evident whether the PSA tests will have further effects on mortality rates.
authors.affiliation: Department of Urology, Helios Agnes Karll Hospital, Bad Schwartau, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Rohde
authors.forename: W
authors.initials: W
authors.lastname: Weidner
authors.forename: A
authors.initials: A
authors.lastname: Katalinic
mesh_terms: D000368:Aged; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality
chemical_list: D017430:Prostate-Specific Antigen